Oenon Holdings, Inc.

Oenon Holdings, Inc., established in 1920 and headquartered in Tokyo, Japan, operates as a diversified enterprise. The company's business foundation lies in biotechnologies derived from fermentation, enabling it to engage in a broad range of sectors. Its primary activities encompass the development and production of alcoholic beverages, various food products, specialized enzymes, and pharmaceuticals, alongside interests in real estate and other ventures. The alcoholic beverage division offers an extensive selection, including traditional Japanese shochu, sake, and umeshu plum wine, alongside chu-hi, processed liquors, and diverse wines. It also supplies brewing and industrial alcohol, as well as a variety of seasonings. For industrial and food applications, Oenon manufactures and markets numerous enzymes. These include lactase (a lactose hydrolytic enzyme), cellulase (for dietary fiber processing), glucose isomelase (used in fructose corn syrup production), protease (a proteolytic enzyme), dispase (for cell dispersion), and isoamylase (for starch processing). In the pharmaceutical segment, the company provides active pharmaceutical ingredients such as Pravastatin, utilized for managing hyperlipidemia, and Voglibose, for diabetes mellitus treatment. This division further produces starch for food processing, diagnostic medical products, and health-focused dietary supplements. Beyond these areas, Oenon Holdings engages in the sale and leasing of real estate properties. Its comprehensive operations also include transportation, cargo handling, and sundry other business activities, completing its multifaceted portfolio.